Table 1.
Characteristics | Number (%) or Median (IQ) | p-Value | |
---|---|---|---|
4 Cycles Delivered | 5 Cycles Delivered | ||
Patients | |||
Number of patients | 55 | 154 | |
Age (years) | 47.0 (42.0–53.7) | 47.4 (39.8–53.5) | 0.690 |
Tobacco use | 20/55 (36.4) | 51/154 (33.1) | 0.740 |
PS | |||
0 | 23/55 (41.9) | 92/154 (59.7) | 0.055 |
1 | 28/55 (50.9) | 57/154 (37.0) | |
2 | 4/55 (7.3) | 5/154 (3.2) | |
Tumors | |||
SCC | 48/55 (87.3) | 124/154 (80.5) | 0.308 |
Poor differentiation | 16/55 (29.1) | 30/154 (19.5) | 0.184 |
FIGO stage | |||
IB1 | 0/55 (0) | 4/154 (2.6) | 0.011 * |
IB2 | 17/55 (30.9) | 42/154 (27.3) | |
IIA | 0/55 (0) | 11/154 (7.1) | |
IIB | 21/55 (38.2) | 72/154 (46.8) | |
IIIA | 0/55 (0) | 4/154 (2.6) | |
IIIB | 9/55 (16.4) | 6/154 (3.9) | |
IVA | 3/55 (5.5) | 3/154 (1.9) | |
IVB | 5/55 (9.1) | 12/154 (7.8) | |
Pelvic nodal metastases | 23/55 (41.8) | 60/154 (40) | 0.640 |
Neutrophilia at diagnosis | 13/43 (30.2) | 29/132 (22.0) | 0.306 |
Treatments | |||
Cycle during IGABT | 21/55 (38.2) | 80/154 (51.9) | 0.086 |
OTT (days) | 47 (43–52) | 48 (44–52) | 0.164 |
CTVHR volume (cm3) | 26.6 (18.5–40.9) | 21.4 (16.3–28.1) | 0.014 * |
D90CTVIR (Gy EQD2) | 67.2 (60.8–70.0) | 68.5 (66.2–72.0) | 0.006 * |
D90CTVHR (Gy EQD2) | 78.7 (74.0–86.1) | 82.8 (74.9–90.4) | 0.014 * |
TRAK | 1.80 (1.58–1.96) | 1.74 (1.57–1.93) | 0.328 |
2 fractions used | 12/55 (21.1) | 15/154 (9.7) | 0.031 * |
ADK: adenocarcinoma; CTV: clinical target volume; cm3: cubic centimeters; EBRT: external beam radiotherapy; Gy: Gray; HR: High Risk; IR: intermediate risk, EQD2: equivalent dose in 2Gy fraction; IGABT: image guided adaptive brachytherapy; IQ: interquartile 25–75; OTT: overall treatment time, including EBRT and IGABT; PAN: para-aortic node; PS: performance status; SCC: squamous cell carcinoma; *: significant comparison; FIGO: Fédération Internationale de Gynécologie Obstétrique.